Serum amlyoid A (SAA) was shown to act as biomarker for exacerbation of chronic obstructive pulmonary disease (AE-COPD). It seems that SAA triggers chronic inflammation by binding to ALX/PFR2 receptor. In contrast, lipoxin A4 seems to inhibit the inflammatory processes by binding to ALX/PFR2 receptor. A small trial has already demonstrated an imbalance between SAA and lipoxin A4 during AE-COPD. This study evaluates SAA level and SAA/lipoxin A4 ratio in patients with stable COPD and AE-COPD.
Patient enrolment and data aquisition is to be carried out on a prospective basis. It is planned to enrol 40 patients with stable COPD and 40 patients with AE-COPD. All patients will undergo blood sampling inlcuding SAA and Lipoxin A4.
Study Type
OBSERVATIONAL
Enrollment
80
Thoraxklinik Heidelberg
Heidelberg, Germany
RECRUITINGSAA
SAA level in stable COPD and COPD exacerbation
Time frame: time of exacerbation/hospitalisation, an average of 3 days
SAA/lipoxin A4 ratio
SAA/lipoxin A4 ratio in stable COPD and COPD exacerbation
Time frame: time of exacerbation/hospitalisation, an average of 3 days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.